Medical devices, healthcare technology and the business of care
510(k) clearance · K262763

iLet Dosing Decision Software

Beta Bionics, Inc. · Decision date Sep 11, 2026

MEDTECHLEDGER EXPLANATIONK262763

What did the FDA decide?

On September 11, 2026, the FDA recorded a substantially equivalent (SESE) decision for K262763, the iLet Dosing Decision Software from Beta Bionics, Inc. of Irvine, California. This is a 510(k) clearance, not a premarket approval. The submission, dated August 3, 2026 and received August 4, 2026, covers a modification of the cleared iLet Dosing Decision Software (K232224) under 21 CFR 862.1356, Class II, product code QJI, in the Clinical Chemistry specialty.

The recorded change is a new user interface, the iLet Mobile App, replacing the iLet Bionic Pancreas interface, plus an individual meal reset feature that returns the learning for Breakfast, Lunch or Dinner to the weight-based default. The summary describes the device as identical to the predicate in intended use, communication with an ACE pump, required user inputs, maximum basal rate, glucose targets, and bolus limits. The summary document ends at a heading for non-clinical testing and special controls; the testing detail and any clinical performance data are not present in the public information.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Clinical Chemistry
Decision date
Sep 11, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262763
Regulatory pathway
510(k) premarket notification
Product code
QJI
Decision code
SESE
Decision date
Sep 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Interoperable Automated Glycemic Controller.

Product code
QJI
FDA device class
2

FDA decision timeline

  1. K262763 received

    Application receipt date recorded by FDA.

  2. K262763 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QJI

Product / regulatory recordCompanyPathwayDecision dateSource
Deka Research and Development Corp.510(k) clearanceOct 15, 2026FDA
CamDiab510(k) clearanceSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Beta Bionics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Irvine, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records